Gynecological Endocrinology最新文献

{"title":"GnRH ability to release FSH and LH in women with functional hypothalamic amenorrhea: a retrospective cohort study about women with and without polycystic ovarian morphology.","authors":"Marlene Hager, Antonella Patsch, Sophie Luise Thieme, Geoffroy Robin, Didier Dewailly, Johannes Ott","doi":"10.1080/09513590.2025.2495604","DOIUrl":"https://doi.org/10.1080/09513590.2025.2495604","url":null,"abstract":"<p><p>Nearly 50% of women with functional hypothalamic amenorrhea (FHA) reveal polycystic ovarian morphology (PCOM), a known risk factor for ovarian hyperstimulation syndrome. However, gonadotropin releasing hormone-agonist (GnRH-a) triggers are not recommended in FHA, since an inadequate endogenous surge in luteinizing hormone (LH) is expected. We aimed to challenge this concept and evaluated LH levels after GnRH stimulation in FHA-women with and without PCOM. In a retrospective cohort study, 82 women with FHA, who underwent a GnRH stimulation test, were included. Thirty-five women revealed PCOM (42.7%). Twenty minutes after GnRH stimulation, there was an increase of serum LH levels in FHA-PCOM (median basal: 2.7 mIU/mL, IQR 1.1-4.6 versus median stimulated: 13.5 mIU/mL, IQR 7.8-21.6, <i>p <</i> 0.001) and in FHA-nonPCOM patients (median basal: 2.5 mIU/mL, IQR 0.5-3.9 versus median stimulated: 5.7 mIU/mL, IQR 2.4-13.9, <i>p <</i> 0.001). Overall, positive correlations (<i>p <</i> 0.001) were found between basal and stimulated LH levels. In FHA-PCOM patients, 42.9% of patients revealed stimulated LH levels >15 mIU/mL, while this was the case in 19.1% of FHA-nonPCOM patients (<i>p =</i> 0.034). In women with FHA-PCOM, ovulation induction with a GnRH-a trigger might be feasible. Future research should focus on the prediction of an adequate response to GnRH triggers in the IVF setting.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2495604"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel serum biomarkers for early diagnosis of gestational diabetes mellitus-a review.","authors":"Michał Kunicki, Natalia Rzewuska, Paulina Sopońska, Agata Pawłosek, Iwona Sowińska, Anna Kloska","doi":"10.1080/09513590.2025.2455472","DOIUrl":"10.1080/09513590.2025.2455472","url":null,"abstract":"<p><p>Gestational diabetes mellitus (GDM) affects 9-25% of pregnancies. Undiagnosed or poorly managed GDM is associated with both short- and long-term complications in the fetus and mother. The pathogenesis of GDM is complex and has not yet been fully elucidated. Several biomarkers found in maternal serum have the potential for the early diagnosis of GDM. The aim of this narrative review was to explore novel biomarkers that have not been comprehensively described in previous reviews. We believe these biomarkers may allow for the detection of GDM in the early stages of pregnancy, enabling timely proper treatment and potentially preventing complications for both the mother and the fetus.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2455472"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daidzein-rich isoflavone aglycones inhibit 17β-hydroxysteroid dehydrogenase 1 and increase estrogen sulfotransferase in endometriosis.","authors":"Yosuke Tarumi, Osamu Takaoka, Yuko Izumi, Akihisa Katayama, Koki Shimura, Hiroyuki Okimura, Hisashi Kataoka, Fumitake Ito, Izumi Kusuki, Jo Kitawaki, Taisuke Mori","doi":"10.1080/09513590.2025.2516202","DOIUrl":"https://doi.org/10.1080/09513590.2025.2516202","url":null,"abstract":"<p><strong>Objective: </strong>Endometriosis is an estrogen-dependent disease wherein isoflavones interact with estrogen receptors. Daidzein-rich isoflavone aglycones (DRIAs) have been shown to inhibit cell proliferation and aromatase activity in vitro and in vivo. This study aims to investigate the effects of DRIAs on the enzymes involved in estrogen metabolism in endometriosis.</p><p><strong>Study design: </strong>Stromal cells isolated from ovarian endometriomas (OESCs) were cultured with DRIAs. Ovarian endometrioma (OE) specimens were obtained from patients who were treated with or without DRIAs. The gene expressions involved in estrogen metabolism and 17β-hydroxysteroid dehydrogenase (HSD17β) 1 activity were analyzed using RT-PCR and thin layer chromatography, respectively.</p><p><strong>Results: </strong>HSD17β1 expression in OE specimens was evaluated using immunohistochemical staining. DRIA treatment significantly suppressed HSD17β1 expression and elevated estrogen sulfotransferase (EST) levels in OESCs; however, no differences were observed in HSD17β2, HSD17β7, HSD17β12, and steroid sulfatase (STS) levels. HSD17β1 enzyme activity was inhibited by DRIAs. Furthermore, immunohistochemical analysis confirmed that HSD17β1 expression was suppressed in the OE specimens of patients undergoing treatment with DRIAs.</p><p><strong>Conclusions: </strong>DRIA treatment could suppress abnormal estrogen production via EST stimulation as well as the inhibition of aromatase and HSD17β1 activities, suggesting therapeutic potential in endometriosis that needs to be confirmed by our ongoing clinical trial. ay.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2516202"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uterus transplantation and the complex motivations behind absolute uterine factor infertility.","authors":"José Maria Soares Junior, Dani Ejzenberg, Peter Chedraui, Edmund Chada Baracat","doi":"10.1080/09513590.2025.2523418","DOIUrl":"https://doi.org/10.1080/09513590.2025.2523418","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2523418"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond pain: employment status affects endometriosis-associated quality of life - a cross-sectional study.","authors":"Jonas Vibert, Inès Ben Jazia, Milena Alec, Giuseppe Benagiano, Nicola Pluchino","doi":"10.1080/09513590.2025.2524496","DOIUrl":"10.1080/09513590.2025.2524496","url":null,"abstract":"<p><p><b>Background</b>: Endometriosis is a chronic condition affecting physical health, emotional well-being, and socioeconomic stability. While pain is a well-recognized determinant of health-related quality of life (HR-QoL), the role of pain experience over employment status remains underexplored. <b>Objective</b>: To determine among women with endometriosis whether employment status independently contributes to HR-QoL, beyond clinical symptoms. <b>Methods:</b> This cross-sectional study was conducted at the University Hospital of Geneva. Women with a confirmed diagnosis of endometriosis were included. Employment status was categorized as full-time employment (>80%), part-time employment (≤80%), voluntary unemployment, and involuntary unemployment. HR-QoL was measured using the Endometriosis Health Profile-30 (EHP-30). <b>Results:</b> A total of 324 patients were included (mean age 32 ± 7.2 years); 78.2% had deep infiltrating endometriosis, and 34.5% reported prior surgery. Regarding employment, 63.2% were employed (51.5% full-time, 11.7% part-time), while 36.7% were unemployed, including 26.2% by choice. Full-time and part-time employment were linked to lower EHP-30 pain scores, with part-time employment showing a stronger association (β = -34.48, 95% CI: -58.00 to -10.88, <i>p</i> = 0.006) than full-time employment (β = -20.57, 95% CI: -40.70 to -0.43, <i>p</i> = 0.046). Unemployed women actively seeking work exhibited worse HR-QoL, particularly in social support (β  = 34.95, 95% CI: 1.89 to 70.80, <i>p</i> = 0.048) and overall HR-QoL burden (β  = 168.27, 95% CI: 30.60 to 205.91, <i>p</i> = 0.019). <b>Conclusion</b>: Employment status is an independent predictor of HR-QoL in women with endometriosis. Beyond pain, professional identity and social integration play key roles in endometriosis burden.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2524496"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The protective role of BMP-15 in infertility development with NLRP3 and IL-18 in infertility development in obese patients with PCOS: clinical and mouse model investigations.","authors":"Qiaohong Guo, Yongjun Zhou, Lingli Li, Xi Chen, Liang Sun","doi":"10.1080/09513590.2025.2530571","DOIUrl":"https://doi.org/10.1080/09513590.2025.2530571","url":null,"abstract":"<p><p><b>Background:</b> Obesity-related polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with infertility and metabolic dysfunction. While bone morphogenetic protein-15 (BMP-15) plays a recognized role in ovarian function, its specific impact on infertility in obese PCOS patients remains unclear <b>Objective:</b> This study aimed to investigate the influence of BMP-15, NOD-like receptor protein 3 (NLRP3), and interleukin-18 (IL-18) on infertility in this population and to evaluate their predictive clinical value. <b>Methods:</b> Clinical data from 185 obese PCOS patients were retrospectively analyzed. Univariate and logistic regression analyses identified infertility-related factors. <b>Results:</b> Results showed an infertility rate of 34.43%, with significant differences in BMP-15, NLRP3, IL-18, Morisky Medication Adherence Scale (MMAS-8), and Connor-Davidson Resilience Scale (CD-RISC) scores between infertility and non-infertility groups. NLRP3, IL-18, and MMAS-8 emerged as risk factors, while BMP-15 and CD-RISC were protective.In an obese PCOS mouse model, BMP-15 administration improved metabolic parameters, restored hormonal balance, reduced ovarian inflammation, and preserved fertility. <b>Conclusion:</b> These findings suggest that BMP-15 plays a protective role in PCOS-related infertility by modulating metabolic and inflammatory pathways. BMP-15 may serve as a valuable biomarker and therapeutic target for early identification and intervention in obese PCOS patients at risk of infertility.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2530571"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontiers of premature ovarian insufficiency research: an analysis from the top 100 most influential articles in the field.","authors":"Cheng Cheng, Suhua Liu, Ziqing Yu, Kexuan Zhu, Rui Liu, Xuhao Li, Jing Zhang","doi":"10.1080/09513590.2025.2470986","DOIUrl":"10.1080/09513590.2025.2470986","url":null,"abstract":"<p><p>Objectives: Premature ovarian insufficiency (POI) is a serious condition that affects women worldwide, In recent years, the number of research publications on POI has increased over the last decades because of the advancement of cutting-edge research in gynecology and the deepening of disciplinary interactions. At the same time, there is a more urgent need to systematically analyze and review existing studies to generalize the research paradigm and disciplinary structure of the field under technological changes.</p><p><p>Materials and methods: We selected the top 100 most cited papers in the Web of Science (WOS) SCI-Expanded database. Knowledge graphs were constructed through the VOS viewer, Cite Space, and Scimago Graphica software, and then relevant information retrieved from the literature was edited using Excel to assess research priorities and trends in the field.</p><p><p>Results: A total of 53 periodicals from 34 different nations and regions published the 100 most-cited publications between 1999 and 2024. The Journal of Clinical Endocrinology & Metabolism published the majority of the papers, while The Lancet had the highest average number of citations per piece. The United States of America produced the highest contribution in terms of publications, with China and France closely trailing after. In terms of total publications, Erasmus MC, Shanghai Jiao Tong University, and Shandong University each contributed the highest number of papers. The main categories were obstetrics and gynecology, endocrinology and metabolism, and reproductive biology. The top five keywords were: failure, women, ANTI-MULLERIAN HORMONE, NATURAL MENOPAUSE, and AGE. The study of HERITAGE AND GENETICS, CARDIOVASCULAR DISEASES, and CELL BIOLOGY AND IMMUNOGENETICS is becoming more and more popular in POI, as shown by cluster analysis.</p><p><p>Conclusions: Bibliometric analysis enables POI researchers to efficiently and visibly pinpoint the cutting-edge areas and focal points of their study. Potential topics of future study may include genetic and molecular biological pathways, cardiovascular pathology, and immunology.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2470986"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex hormone-binding globulin as a biomarker for metabolic risk in European women with polycystic ovary syndrome.","authors":"Bo E van Bree, Denise M B van der Heijden, Ron J T van Golde, Martijn C G J Brouwers, Marc E A Spaanderman, Olivier Valkenburg","doi":"10.1080/09513590.2025.2500462","DOIUrl":"https://doi.org/10.1080/09513590.2025.2500462","url":null,"abstract":"<p><strong>Objective: </strong>Sex hormone-binding globulin (SHBG) is suggested to be a biomarker for metabolic disturbances in women with polycystic ovary syndrome (PCOS). Insulin resistance and hyperinsulinemia is common in PCOS patients. Low SHBG increases free testosterone levels, which further induces hyperinsulinemia. There is no established cutoff level for SHBG in PCOS patients. The goal of this study is to examine SHBG as a biomarker for metabolic dysregulation in European women with PCOS in relation to hyperandrogenemia.</p><p><strong>Methods: </strong>Retrospective data was collected from the outpatient clinic for menstrual cycle disorders at Maastricht University Medical Center+. 208 women were included, aged between 18 and 40 years old. During a one-time visit to the clinic, physical examination and vaginal ultrasound evaluation were performed as well as endocrine evaluation performed after overnight fast. The women were diagnosed with PCOS according to the European Society of Human Reproduction and Embryology (ESHRE) 2018 guideline.</p><p><strong>Results: </strong>BMI was inversely associated with SHBG (β -0.598, 95% CI [-0.710 to -0.485]) and waist circumference (β -0.604, [-0.715 to -0.492]), even after correction for HOMA-IR and testosterone. A cutoff level <40 nmol/L was significantly, and unfavorably, associated with all metabolic outcomes. Its AUROC was optimal for waist circumference (sensitivity 0.75, specificity 0.82).</p><p><strong>Conclusions: </strong>SHBG levels <40 nmol/L are indicative for metabolic dysregulation in European women with PCOS. Waist circumference is an important predictor for SHBG, comparable to BMI. Visceral adiposity might play an important role in the expression of SHBG and etiology of PCOS.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2500462"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in menopause-specific quality of life between women with transdermal estradiol versus oral estrogens: results of a randomized controlled trial.","authors":"Ruiyi Tang, Yubo Fan, Xiangyan Ruan, Zhifen Zhang, Mulan Ren, Jie Wu, Kuanyong Shu, Huirong Shi, Meiqing Xie, Shulan Lv, Xin Yang, Qi Yu, Rong Chen","doi":"10.1080/09513590.2025.2484213","DOIUrl":"10.1080/09513590.2025.2484213","url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy of oral and transdermal estrogens in improving the quality of life in perimenopausal and recently postmenopausal women.</p><p><strong>Methods: </strong>257 women aged 40-55 years, within three years after their final menstrual period were randomized to receive transdermal oestrogel (t-E2) (<i>n</i> = 128) or oral estradiol valerate (o- E2V) (<i>n</i> = 129; both with micronized progesterone 200 mg for 14 days each month). Menopausal symptoms were recorded at screening and at 4, 12, and 24 weeks post-randomization. Menopausal symptoms were evaluated using the Menopause-Specific Quality of Life (MENQOL) questionnaire.</p><p><strong>Results: </strong>Significant improvements of MENQOL scores were observed in both groups compared with baseline. The decrease of MENQOL scores after treatment showed almost no difference between the two groups (<i>p</i> > 0.05) except the VMS domain which indicated a better result in oral estrogen group after 24 weeks.</p><p><strong>Conclusions: </strong>This study showed that both transdermal and oral estrogens were highly effective in relieving the overall menopausal symptoms for recently-menopausal women, with little difference in treatment efficacy between the two routes.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2484213"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"circRNA_BMPR2 affects the progression of polycystic ovary syndrome by regulating the expression of Rab43.","authors":"Wang Liping, Tao Chenyue, Chen Shuai, Gui Liu, Zhang Yitong, Jiang Min, Zhou Dongjie, Zhou Luojing","doi":"10.1080/09513590.2025.2526559","DOIUrl":"https://doi.org/10.1080/09513590.2025.2526559","url":null,"abstract":"<p><p>Polycystic Ovary Syndrome (PCOS) is a common reproductive and metabolic disorder causing infertility in women of childbearing age.Circular RNAs are known to be involved in PCOS development, but their regulatory mechanisms remain unclear. This study explored the role of circ_BMPR2 in PCOS to advance early diagnosis and treatment.It found elevated circ_BMPR2 expression in ovarian granulosa cells of PCOS patients. Knocking down of circ_BMPR2 inhibited proliferation and promoted apoptosis in KGN cell. Mechanistically, we confirmed that circ_BMPR2 acts as a sponge to bind miR-619-5p, which could specifically target Rab43 gene.PCOS tissues showed upregulated Rab43, and silencing circ_BMPR2 reduced Rab43 levels, rescued by a miR-619-5p inhibitor. Further experiments confirmed that overexpression of Rab43 reversed the effects of circ_BMPR2 knockdown on cell proliferation and apoptosis in KGN cells. Thus,our findings implicate circ_BMPR2 acts as a key player in PCOS process, by modulating growth and cell cycle progression of GCs through regulating the miR-619-5p/Rab43 axis. This suggests that circ_BMPR2 could be a prospective biomarker for the early diagnosis of PCOS. By understanding its molecular mechanisms, we can pave the way for more effective interventions to treat this complex disease.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2526559"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}